אלביומין % 20 ישראל - עברית - Ministry of Health

אלביומין % 20

kamada ltd, israel - plasma protein fraction - תמיסה לאינפוזיה - plasma protein fraction 200 mg/ml - protein c - protein c - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient, based on official recommendation.

גרדסיל ישראל - עברית - Ministry of Health

גרדסיל

merck sharp & dohme israel ltd - protein l1 (type 11); protein l1 (type 16); protein l1 (type 18); protein l1 (type 6) - תרחיף להזרקה - protein l1 (type 18) 20 mcg / 0.5 ml; protein l1 (type 6) 20 mcg / 0.5 ml; protein l1 (type 11) 40 mcg / 0.5 ml; protein l1 (type 16) 40 mcg / 0.5 ml - combinations - combinations - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years* of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations..

בקסרו ישראל - עברית - Ministry of Health

בקסרו

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - תרחיף להזרקה - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine